European Journal of Clinical Pharmacology

, Volume 62, Issue 8, pp 589–595

Iloprost for prevention of contrast-mediated nephropathy in high-risk patients undergoing a coronary procedure. Results of a randomized pilot study

  • K. Spargias
  • E. Adreanides
  • G. Giamouzis
  • S. Karagiannis
  • A. Gouziouta
  • A. Manginas
  • V. Voudris
  • G. Pavlides
  • D. V. Cokkinos
Clinical Trials



The prevention of contrast-mediated nephropathy (CMN), which accounts for considerable morbidity and mortality, remains a vexing problem. Contrast induced renal vasoconstriction is believed to play a pivotal role in the CMN mechanism. The aim of this pilot study was to examine the safety and efficacy of two doses of the prostacyclin analogue iloprost in preventing CMN in high-risk patients undergoing a coronary procedure.


Forty-five patients undergoing coronary angiography and/or intervention who had a serum creatinine concentration ≥1.4 mg/dL were randomized to receive iloprost at 1 or 2 ng/kg/min or placebo, beginning 30–90 minutes before and terminating 4 hours after the procedure. CMN was defined by an absolute increase of serum creatinine ≥0.5 mg/dL or a relative increase of ≥25% measured 2 to 5 days after the procedure. Study drug infusion was discontinued in 2 patients in the low-dose iloprost group due to flush/nausea and in 5 patients in the high-dose group due to severe hypotension.


The mean creatinine concentration change in the placebo group (0.02 mg/dL) was unfavorable compared to that in the low-dose iloprost group (−0.11 mg/dL; p=0.08) and high-dose iloprost group (−0.23 mg/dL; p=0.048). The difference between the absolute changes in creatinine clearance was favorable compared to placebo for both the low (mean difference 6.1 mL/min, 95%CI −0.5 to 12.8 mL/min, p=0.07) and the high-dose iloprost group (11.8 mL/min, 95%CI 4.7 to 18.8 mL/min, p=0.002). Three cases of CMN were recorded; all in the placebo group (p=0.032).


The results of this pilot study suggest that prophylactic administration of iloprost may effectively prevent CMN, but higher dosages are connected with substantial tolerability issues.


Contrast nephropathy Coronary angiogrphy Iloprost Prostacyclin Prostaglandins 


  1. 1.
    Brick R, Krzossok, Markowetz F, Schnulle P, van der Woude FJ. Braun C (2003) Acetylcysteine for prevention of contrast nephropathy: meta-analysis. Lancet 362:598–603CrossRefGoogle Scholar
  2. 2.
    McCullough PA, Wolyn R, Rocher LL, Levin RN, O’Neill WW (1997) Acute renal failure after coronary intervention: incidence, risk factors, and relationship to mortality. Am J Med 103:368–375PubMedCrossRefGoogle Scholar
  3. 3.
    Gruberg L, Mintz GS, Mehran R et al (2000) The prognostic implications of further renal function deterioration within 48 h of interventional coronary procedures in patients with pre-existent chronic renal failure. J Am Coll Cardiol 36:1542–1548PubMedCrossRefGoogle Scholar
  4. 4.
    Solomon R, Werner G, Mann D, D’Elia J, Silva P (1994) Effects of saline, mannitol, and furosemide on acute decreases in renal function induced by radiocontrast agents. N Engl J Med 331:1416–1420PubMedCrossRefGoogle Scholar
  5. 5.
    Rihal CS, Textor SC, Grill DE et al (2002) Incidence and prognostic impostance of acute renal failure after percutaneous coronary intervention. Circulation 105:2259–2264PubMedCrossRefGoogle Scholar
  6. 6.
    Best PJ, Lennon R, Ting HH et al (2002) The impact of renal insufficiency on clinical outcomes in patients undergoing percutaneous coronary interventions. J Am Coll Cardiol 39:1113–1119PubMedCrossRefGoogle Scholar
  7. 7.
    Berns AS (1989) Nephrotoxicity of contrast media. Kidney Int 36:730–740PubMedCrossRefGoogle Scholar
  8. 8.
    Maeder M, Klein M, Fehr T, Rickli H (2004) Contrast nephropathy: review focusing on prevention. J Am Coll Cardiol 44:1763–1771PubMedCrossRefGoogle Scholar
  9. 9.
    Brezis M, Rosen S (1995) Hypoxia of the renal medulla - Its implications for disease. N Engl J Med 332:647–655PubMedCrossRefGoogle Scholar
  10. 10.
    Schlondorff D (1986) Renal prostaglandin synthesis: sites of production and specific actions of prostaglandins. Am J Med 81(suppl 2B):1–11PubMedCrossRefGoogle Scholar
  11. 11.
    Heyman SN, Rosen S, Brezis M (1994) Radiocontrast nephropathy: a paradigm for the synergism between toxic and hypoxic insults in the kidney. Exp Nephrol 2:153–157PubMedGoogle Scholar
  12. 12.
    Sketch MH Jr, Whelton A, Schollmayer E, Koch JA, Bernink PJ, Woltering F et al (2001) Prostaglandin E1 Study Group: prevention of contrast media-induced renal dysfunction with prostaglandin E1: a randomized, double-blind, placebo-controlled study. Am J Ther 8:155–162PubMedCrossRefGoogle Scholar
  13. 13.
    Paller MS, Manivel JC (1992) Prostaglandins protect kidneys against ischemic and toxic injury by a cellular effect. Kidney Int 42:1345–1354PubMedCrossRefGoogle Scholar
  14. 14.
    Krause W, Muschick P, Kruger U (2002) Use of near-infrared reflection spectroscopy to study the effects of X-ray contrast media on renal tolerance in rats: effects of a prostacyclin analogue and of phosphodiesterase inhibitors. Invest Radiol 37:698–705PubMedCrossRefGoogle Scholar
  15. 15.
    Itoh Y, Yano T, Sendo T, Oishi R (2005) Clinical and experimental evidence for prevention of acute renal failure induced by radiographic contrast media. J Pharmacol Sci 97:473–488PubMedCrossRefGoogle Scholar
  16. 16.
    Yano T, Itoh Y, Kubota T, Sendo T, Oishi R (2004) A prostacyclin analog beraprost sodium attenuates radiocontrast media-induced LLC-PK1 cells injury. Kidney Int 65:1654–1663PubMedCrossRefGoogle Scholar
  17. 17.
    Cockcroft DW, Gault MH (1976) Prediction of creatinine clearance from serum creatinine. Nephron 16:31–41PubMedCrossRefGoogle Scholar
  18. 18.
    Solomon R (2005) The role of osmolality in the incidence of contrast induced nephropathy: a systematic review of angiographic contrast media in high risk patients. Kidney Int 68:2256–2263PubMedCrossRefGoogle Scholar
  19. 19.
    Wigley FM, Wise RA, Seibold JR, McCloskey DA, Kujala G, Medsger TA et al (1994) Intravenous iloprost infusion in patients with Raynaud phenomenon secondary to systemic sclerosis. A multicenter, placebo-controlled, double-blind study. Ann Intern Med 120:199–206PubMedGoogle Scholar
  20. 20.
    Moncada S, Vane JR (1981) Prostacyclin and blood coagulation. Drugs 21:430–437PubMedCrossRefGoogle Scholar
  21. 21.
    Zusman RM, Crow JW, Cato AE, Tolkoff-Rubin N (1981) Effects of prostacyclin infusion in uremic patients: hematologic and hemodynamic responses. Clin Pharmacol Ther 30:251–257PubMedCrossRefGoogle Scholar
  22. 22.
    Spargias K, Alexopoulos E, Kyrzopoulos S, Iacovis P, Greenwood DC, Manginas A et al (2004) Ascorbic acid prevents contrast-mediated nephropathy in patients with renal dysfunction undergoing coronary angiography or intervention. Circulation 110:2837–2842PubMedCrossRefGoogle Scholar
  23. 23.
    Heller R, Werner-Felmayer G, Werner ER (2005) Antioxidants and endothelial nitric oxide synthesis Eur J Clin Pharmacol 11:1–8 (published ahead of print), NovGoogle Scholar
  24. 24.
    Rudnick MR, Goldfarb S (2003) Pathogenesis of contrast- induced nephropathy: experimental and clinical observations with an emphasis on the role of osmolality. Rev Cardiovasc Med 4:S28–S33PubMedGoogle Scholar
  25. 25.
    Liss P, Nygren A, Olsson U et al (1996) Effects of contrast media and mannitol on renal medullary blood flow and aggregation in the rat kidney. Kidney Int 49:1268–1275PubMedCrossRefGoogle Scholar
  26. 26.
    Workman RJ, Shaff MI, Jackson RV, Diggs J, Frazer MG, Briscoe C (1983) Relationship of renal hemodynamic and functional changes following intravascular contrast to the renin-angiotensin system and renal prostacyclin in the dog. Invest Radiol 18:160–166PubMedCrossRefGoogle Scholar
  27. 27.
    Turker RK, Demirel E, Ercan ZS (1988) Iloprost preserves kidney function against anoxia. Prostaglandins Leukot Essent Fat Acids 31:45–52CrossRefGoogle Scholar
  28. 28.
    Lifschitz MD, Barnes JL (1984) Prostaglandin I2 attenuates ischemic acute renal failure in the rat. Am J Physiol 247:F714–F717PubMedGoogle Scholar
  29. 29.
    Agmon Y, Peleg H, Greenfeld Z, Rosen S, Brezis M (1994) Nitric oxide and prostanoids protect the renal outer medulla from radiocontrast toxicity in the rat. J Clin Invest 94:1069–1075PubMedCrossRefGoogle Scholar
  30. 30.
    Fujita T, Fuke Y, Satomura A, Hidaka M, Ohsawa I, Endo M et al (2001) PGI2 analogue mitigates the progression rate of renal dysfunction improving renal blood flow without glomerular hyperfiltration in patients with chronic renal insufficiency. Prostagl Leukot Essent 65:223–227CrossRefGoogle Scholar
  31. 31.
    Morgera S, Woydt R, Kern H, Schmutzler M, DeJonge K, Lun A et al (2002) Low-dose prostacyclin preserves renal function in high-risk patients after coronary bypass surgery. Crit Care Med 30:107–112PubMedCrossRefGoogle Scholar
  32. 32.
    Boie Y, Rushmore TH, Darmon-Goodwin A, Grygorczyk R, Slipetz DM, Metters KM et al (1994) Cloning and expression of a cDNA for the human prostanoid IP receptor. J Biol Chem 269:12173–12178PubMedGoogle Scholar
  33. 33.
    Komhoff M, Lesener B, Nakao K, Seyberth HW, Nusing RM (1998) Localization of the prostacyclin receptor in human kidney. Kidney Int 54:1899–1908PubMedCrossRefGoogle Scholar
  34. 34.
    Breyer MD (1998) Prostaglandin receptors in the kidney: a new route for intervention. Exp Nephrol 6:180–188PubMedCrossRefGoogle Scholar
  35. 35.
    Yano T, Itoh Y, Kubota T, Sendo T, Koyama T, Fujita T et al (2005) A prostacyclin analog prevents radiocontrast nephropathy via phosphorylation of cyclic AMP response element binding protein. Am J Pathol 166:1333–1342PubMedGoogle Scholar

Copyright information

© Springer-Verlag 2006

Authors and Affiliations

  • K. Spargias
    • 1
    • 2
  • E. Adreanides
    • 1
  • G. Giamouzis
    • 1
  • S. Karagiannis
    • 1
  • A. Gouziouta
    • 1
  • A. Manginas
    • 1
  • V. Voudris
    • 1
  • G. Pavlides
    • 1
  • D. V. Cokkinos
    • 1
  1. 1.Onassis Heart CentreAthensGreece
  2. 2.AthensGreece

Personalised recommendations